A high priority to a large majority of the Pharmaceutical Industry is to develop and introduce new cancer drugs. An increasing number of potential drug targets particularly to tumor cells continue to be discovered and studied. By BioProcessing Inc.
Biopharmaceuticals have the potential to cure diseases rather than merely treat symptoms, and have fewer side effects because of their specificity.
The incidence of injury or death from fake, expired, adulterated, mislabeled or otherwise unauthorized medicinal products is rising. The pharmaceutical industry itself is also at major risk.
NGP talks to Robert Arendal, Chairman of the Cool Chain Association of the issues faced by the pharmaceutical supply chain.
PrisymID have been a leading supplier of labelling software solutions to the world's Life Sciences companies for almost 25 years including over 10 years of experience delivering labelling solutions to meet the requirements of 21 CFR Part 11.